Literature DB >> 29336703

Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Prasad S Kulkarni1, Julia L Hurwitz2,3, Eric A F Simões4,5, Pedro A Piedra6.   

Abstract

Correlates of protection (CoPs) can play a significant role in vaccine development by assisting the selection of vaccine candidates for clinical trials, supporting clinical trial design and implementation, and simplifying tests of vaccine modifications. Because of this important role in vaccine development, it is essential that CoPs be defined by well-designed immunogenicity and efficacy studies, with attention paid to benefits and limitations. The respiratory syncytial virus (RSV) field is unique in that a great deal of information about the humoral response is available from basic research and clinical studies. Polyclonal and monoclonal antibodies have been used routinely in the clinic to protect vulnerable infants from infection, providing a wealth of information about correlations between neutralizing antibodies and disease prevention. Considerations for the establishment of future CoPs to support RSV vaccine development in different populations are therefore discussed.

Entities:  

Keywords:  neutralizing antibody; vaccine efficacy

Mesh:

Substances:

Year:  2018        PMID: 29336703      PMCID: PMC5863081          DOI: 10.1089/vim.2017.0147

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  120 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children.

Authors:  Steven Black; Uwe Nicolay; Timo Vesikari; Markus Knuf; Giuseppe Del Giudice; Giovanni Della Cioppa; Theodore Tsai; Ralf Clemens; Rino Rappuoli
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

Review 3.  A guide to the perplexed on the specificity of antibodies.

Authors:  Clifford B Saper
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

Review 4.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

5.  Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.

Authors:  Jennifer Harcourt; Rene Alvarez; Les P Jones; Christine Henderson; Larry J Anderson; Ralph A Tripp
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

6.  Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine.

Authors:  G S Turner
Journal:  J Gen Virol       Date:  1978-09       Impact factor: 3.891

7.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

8.  Antibodies to respiratory syncytial virus polypeptides and their significance in human infection.

Authors:  K A Ward; P R Lambden; M M Ogilvie; P J Watt
Journal:  J Gen Virol       Date:  1983-09       Impact factor: 3.891

9.  Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.

Authors:  Lia M Haynes; Hayat Caidi; Gertrud U Radu; Congrong Miao; Jennifer L Harcourt; Ralph A Tripp; Larry J Anderson
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

10.  Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus.

Authors:  Vivian Luchsinger; Pedro A Piedra; Mauricio Ruiz; Enna Zunino; María Angélica Martínez; Clarisse Machado; Rodrigo Fasce; María Teresa Ulloa; Maria Cristina Fink; Pamela Lara; Luis F Avendaño
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

View more
  12 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

2.  Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.

Authors:  Raul Pellini; Aldo Venuti; Fulvia Pimpinelli; Elva Abril; Giovanni Blandino; Flaminia Campo; Laura Conti; Armando De Virgilio; Federico De Marco; Enea Gino Di Domenico; Ornella Di Bella; Simona Di Martino; Fabrizio Ensoli; Diana Giannarelli; Chiara Mandoj; Valentina Manciocco; Paolo Marchesi; Francesco Mazzola; Silvia Moretto; Gerardo Petruzzi; Fabrizio Petrone; Barbara Pichi; Martina Pontone; Jacopo Zocchi; Antonello Vidiri; Branka Vujovic; Giulia Piaggio; Aldo Morrone; Gennaro Ciliberto
Journal:  EClinicalMedicine       Date:  2021-06-04

3.  An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors:  Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal:  N Engl J Med       Date:  2020-07-14       Impact factor: 91.245

4.  Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.

Authors:  Qingqing Xie; Zhao Wang; Fengyun Ni; Xiaorui Chen; Jianpeng Ma; Nita Patel; Hanxin Lu; Ye Liu; Jing-Hui Tian; David Flyer; Michael J Massare; Larry Ellingsworth; Gregory Glenn; Gale Smith; Qinghua Wang
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

5.  RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization.

Authors:  Sarah Wilmschen; Sabrina Schneider; Felix Peters; Lea Bayer; Leila Issmail; Zoltán Bánki; Thomas Grunwald; Dorothee von Laer; Janine Kimpel
Journal:  Vaccines (Basel)       Date:  2019-07-03

6.  B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV.

Authors:  Johannes F Scheid; Christopher O Barnes; Basak Eraslan; Andrew Hudak; Jennifer R Keeffe; Lisa A Cosimi; Eric M Brown; Frauke Muecksch; Yiska Weisblum; Shuting Zhang; Toni Delorey; Ann E Woolley; Fadi Ghantous; Sung-Moo Park; Devan Phillips; Betsabeh Tusi; Kathryn E Huey-Tubman; Alexander A Cohen; Priyanthi N P Gnanapragasam; Kara Rzasa; Theodora Hatziioanno; Michael A Durney; Xiebin Gu; Takuya Tada; Nathaniel R Landau; Anthony P West; Orit Rozenblatt-Rosen; Michael S Seaman; Lindsey R Baden; Daniel B Graham; Jacques Deguine; Paul D Bieniasz; Aviv Regev; Deborah Hung; Pamela J Bjorkman; Ramnik J Xavier
Journal:  Cell       Date:  2021-04-24       Impact factor: 66.850

Review 7.  Immunopathology of RSV: An Updated Review.

Authors:  Harrison C Bergeron; Ralph A Tripp
Journal:  Viruses       Date:  2021-12-10       Impact factor: 5.048

8.  Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.

Authors:  Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; David M Henke; Kirtida D Patel; Felipe-Andres Piedra; Laura S Angelo; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

Review 9.  Respiratory syntycial virus: Current treatment strategies and vaccine approaches.

Authors:  Elena Margret Thornhill; Jessica Salpor; David Verhoeven
Journal:  Antivir Chem Chemother       Date:  2020 Jan-Dec

10.  SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.

Authors:  Dami A Collier; Anna De Marco; Isabella A T M Ferreira; Bo Meng; Rawlings Datir; Alexandra C Walls; Steven A Kemp S; Jessica Bassi; Dora Pinto; Chiara Silacci Fregni; Siro Bianchi; M Alejandra Tortorici; John Bowen; Katja Culap; Stefano Jaconi; Elisabetta Cameroni; Gyorgy Snell; Matteo S Pizzuto; Alessandra Franzetti Pellanda; Christian Garzoni; Agostino Riva; Anne Elmer; Nathalie Kingston; Barbara Graves; Laura E McCoy; Kenneth Gc Smith; John R Bradley; Nigel Temperton; Lourdes Ceron-Gutierrez L; Gabriela Barcenas-Morales; William Harvey; Herbert W Virgin; Antonio Lanzavecchia; Luca Piccoli; Rainer Doffinger; Mark Wills; David Veesler; Davide Corti; Ravindra K Gupta
Journal:  medRxiv       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.